Gene therapy has been the hyped technology in the biotech sector ever since the CAR-T momentum started to fade. The recent acquisitions of Spark Therapeutics (ONCE) and Nightstar Therapeutics (NITE) has many investors looking into this groundbreaking segment for a lucrative investment in the future of medicine. After catching a big break with ONCE, I have decided to find another potential gene therapy company that is ripe for the picking. Rocket Therapeutics (RCKT) appears to be a strong candidate to fill that role in my speculative portfolio. Admittedly, Rocket